SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
1-Year Return
14.02%
This Quarter Return
+0.25%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$520M
AUM Growth
+$3.52M
(+0.68%)
Cap. Flow
+$13.7M
Cap. Flow
% of AUM
2.64%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
129
New
9
Increased
50
Reduced
34
Closed
11
Top Buys
| 1 |
Mineralys Therapeutics
MLYS
|
$9.6M |
| 2 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$5.08M |
| 3 |
TSVT
2seventy bio
TSVT
|
$4.86M |
| 4 |
Treace Medical Concepts
TMCI
|
$4.7M |
| 5 |
Vera Therapeutics
VERA
|
$4.66M |
Top Sells
| 1 |
Exelixis
EXEL
|
$8.88M |
| 2 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$6.05M |
| 3 |
iRhythm Technologies
IRTC
|
$4.59M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.22M |
| 5 |
Arrowhead Research
ARWR
|
$3.87M |
Sector Composition
| 1 | Healthcare | 95.06% |
| 2 | Industrials | 4.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Incyte
INCY
$16.7B
| $483K | 0.09% |
6,680
| – | – |
|
102
Legend Biotech
LEGN
$6.46B
| $482K | 0.09% |
10,000
+1,000
| +11% | +$48.2K |
|
103
Dr. Reddy's Laboratories
RDY
$11.8B
| $456K | 0.09% |
40,020
-10,000
| -20% | -$114K |
|
104
Royalty Pharma
RPRX
$16B
| $448K | 0.09% |
12,440
| – | – |
|
105
United Therapeutics
UTHR
$17.2B
| $406K | 0.08% |
1,815
| – | – |
|
106
Zai Lab
ZLAB
$3.34B
| $397K | 0.08% |
11,922
-1,500
| -11% | -$49.9K |
|
107
BioNTech
BNTX
$24.9B
| $336K | 0.06% |
2,700
| – | – |
|
108
Jazz Pharmaceuticals
JAZZ
$7.77B
| $318K | 0.06% |
2,170
+200
| +10% | +$29.3K |
|
109
argenx
ARGX
$44.9B
| $317K | 0.06% |
850
-80
| -9% | -$29.8K |
|
110
Neurocrine Biosciences
NBIX
$13.9B
| $283K | 0.05% |
2,800
| – | – |
|
|
FUSN
111
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $216K | 0.04% |
57,297
| – | – |
|
112
Medpace
MEDP
$13.6B
| $182K | 0.04% |
970
| – | – |
|
113
Ascendis Pharma
ASND
$12B
| $181K | 0.03% |
1,690
| – | – |
|
114
Roivant Sciences
ROIV
$8.58B
| $155K | 0.03% |
21,000
| – | – |
|
115
Madrigal Pharmaceuticals
MDGL
$9.61B
| $121K | 0.02% |
+500
| New | +$121K |
|
116
NovoCure
NVCR
$1.34B
| $105K | 0.02% |
1,750
+150
| +9% | +$9.02K |
|
117
Intellia Therapeutics
NTLA
$1.25B
| $92.4K | 0.02% |
2,480
-68,900
| -97% | -$2.57M |
|
118
Summit Therapeutics
SMMT
$17.7B
| $35K | 0.01% |
+20,000
| New | +$35K |
|
|
119
Arrowhead Research
ARWR
$3.87B
| – | – |
-95,400
| Closed | -$3.87M |
|
120
BioXcel Therapeutics
BTAI
$52M
| – | – |
-3,822
| Closed | -$1.31M |
|
121
CRISPR Therapeutics
CRSP
$4.8B
| – | – |
-2,490
| Closed | -$101K |
|
|
122
Exelixis
EXEL
$10.1B
| – | – |
-553,475
| Closed | -$8.88M |
|
123
Fate Therapeutics
FATE
$112M
| – | – |
-183,000
| Closed | -$1.85M |
|
124
Guardant Health
GH
$7.65B
| – | – |
-4,770
| Closed | -$130K |
|
125
Ionis Pharmaceuticals
IONS
$9.46B
| – | – |
-4,450
| Closed | -$168K |
|